PURR · Hyperliquid Strategies Inc Common Stock

Summary

Hyperliquid Strategies Inc (PURR) filed an 8-K/A providing audited financial statements of Sonnet BioTherapeutics Holdings, Inc., the acquired business, as required under Item 9.01 for the fiscal year ended with the filing dated February 18, 2026. This amendment fulfills post-acquisition disclosure obligations following the business combination.

Key takeaways

• Form Type: 8-K/A filed February 18, 2026
• External Item: Item 9.01 - Financial Statements and Exhibits
• Content: Audited financial statements of Sonnet BioTherapeutics Holdings, Inc. as of and for the fiscal year ended
• Company: Hyperliquid Strategies Inc Common Stock (Ticker: PURR)
• Acquired Entity: Sonnet BioTherapeutics Holdings, Inc.